Specialized news

Array ( [0] => stdClass Object ( [id] => 1405 [id_crawler] => [category_product] => NULL [thumbnail] => z7475342255361_6d2a37fa1d1528705dc55057db6a4222.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 0000-00-00 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-01-29 13:20:52 [updated_time] => 2026-01-30 13:30:18 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-and-Phenikaa-hospital-strengthen-professional-exchange-on-preimplantation-genetic-testing [title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing [description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle. [content] =>

Responding to the growing demand for the application of PGT solutions in assisted reproduction, Eurofins GENTIS recently collaborated with Phenikaa Hospital to organize a professional working session. The meeting focused on exchanging insights and updating advanced genetic testing solutions currently applied in reproductive medicine, including specialized technologies and services developed and implemented by Eurofins GENTIS.

Representing Eurofins GENTIS, Dr. Nguyen Quang Vinh (Laboratory Director) directly presented and reported on the professional content at the session. On the Phenikaa Hospital side, the meeting was attended by a team of physicians, specialists, and technicians in assisted reproduction, who engaged in in-depth discussions on the practical application of genetic testing in IVF treatment.

At the meeting, Dr. Vinh provided an overview of the PGT testing system currently implemented at Eurofins GENTIS, with a focus on PGT-A/SR—preimplantation genetic testing for aneuploidies and structural rearrangements. PGT-A/SR enables comprehensive analysis of all 24 chromosomes, detecting numerical and structural abnormalities, including aneuploidy, deletions, duplications, and mosaicism. The application of PGT-A/SR helps IVF clinicians select embryos with higher implantation potential, reduce the risk of early miscarriage, and increase embryo transfer success rates, particularly in advanced-age patients, those with repeated IVF failures, or a history of pregnancy loss. Data shared by Eurofins GENTIS showed that embryos with chromosomal abnormalities account for nearly half of all analyzed samples. This highlights the importance of preimplantation genetic testing, as many embryos with good morphology may still harbor underlying genetic abnormalities that can directly affect pregnancy outcomes if not screened early.

In addition to PGT-A/SR, PGT-M was another topic of particular interest to Phenikaa Hospital. This solution is designed for couples who carry genes associated with inherited diseases but wish to have healthy children free from these conditions. Eurofins GENTIS has currently implemented more than 100 PGT-M protocols for a wide range of conditions such as thalassemia, spinal muscular atrophy (SMA), hemophilia, and other rare genetic disorders, using advanced technologies including next-generation sequencing (NGS), STR, SNP analysis, and karyomapping. The integration of PGT-M with IVF helps prevent genetic diseases at the embryo stage, delivering long-term benefits for the health of future generations.

Within the framework of the session, Dr. Vinh also highlighted Eurofins GENTIS’s testing capacity and internationally standardized laboratory system, featuring the Illumina MiSeq NGS platform and specialized analysis software BlueFuse. Notably, the achievement of CAP accreditation for PGT testing serves as strong evidence of quality, reliability, and standardization across the entire genetic testing workflow at GENTIS.

Beyond introducing genetic testing services and modern laboratory infrastructure, Dr. Nguyen Quang Vinh also directly addressed professional questions from Phenikaa Hospital’s experts and physicians, helping clarify practical issues related to the application of genetic testing in assisted reproduction. Physicians at Phenikaa Hospital highly appreciated the professional insights, real-world data, and testing solutions provided by Eurofins GENTIS, considering them an important foundation for improving treatment outcomes and the quality of care for IVF patients.

The professional exchange between Eurofins GENTIS and Phenikaa Hospital not only held academic value but also opened up directions for sustainable collaboration in training, clinical consultation, and the implementation of advanced genetic testing solutions. Through close cooperation, both parties expect to contribute to improving IVF treatment effectiveness, reducing the psychological and financial burden on patients, and delivering meaningful value to the community in the journey toward fulfilling the dream of having healthy children.

[content_more] => [meta_title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic te [meta_description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babi [meta_keyword] => GENTIS,Phenikaa [thumbnail_alt] => [post_id] => 1405 [category_id] => 15 ) [1] => stdClass Object ( [id] => 1404 [id_crawler] => [category_product] => NULL [thumbnail] => rabbit_media-4214.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-01-23 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-01-23 10:43:46 [updated_time] => 2026-01-30 13:27:57 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Trends-and-applications-of-AI-and-omics-data-in-genetic-testing-and-reproductive-genetic-counseling [title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling [description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling. [content] =>

AI and omics data – The foundation of precision medicine
The rapid development of next-generation sequencing (NGS), mass spectrometry technologies, along with the increasing capacity for collecting and storing large-scale clinical data, has generated an enormous volume of information in medical genetics. Omics data—including genomics, transcriptomics, proteomics (proteins and post-translational modifications), metabolomics (metabolites and hormones), together with bioinformatics and AI—provide a comprehensive reflection of biological characteristics at the molecular level. However, analyzing and effectively exploiting these datasets poses a major challenge if relying solely on traditional methods.

Dr. Pham Dinh Minh (R&D Director, Eurofins GENTIS) presenting at the Symposium on Reproductive Genetics and PGT

With its machine learning capabilities and multidimensional data analysis, AI enables rapid and accurate processing of complex Omics datasets, thereby uncovering potential relationships among genetic factors, clinical data, and disease risks. In assisted reproduction, this opens up opportunities to improve embryo screening quality, predict implantation potential, and provide more scientific and personalized genetic risk counseling for couples.

Eurofins GENTIS pioneers the application of AI in reproductive genetics
According to Dr. Pham Dinh Minh (R&D Director of Eurofins GENTIS) at the Symposium on Reproductive Genetics and PGT, in recent years Eurofins GENTIS has focused on developing information technology platforms and AI applications integrated with Omics data to support genetic screening, counseling, and management of hereditary diseases. These solutions not only provide professional support for hospitals and partners but also strengthen the connection between Eurofins GENTIS, clinicians, healthcare facilities, and patients, contributing to improved user experience and healthcare service quality.

In the field of genetic analysis, Eurofins GENTIS has been researching and developing various bioinformatics tools to support the application of AI in studying the molecular mechanisms of fertilization, embryo development, and factors affecting infertility and subfertility. These studies aim to improve the success rates of in vitro fertilization (IVF) and to personalize treatment for each patient in the future.

PGT-AI – A new approach to embryo selection
One of the greatest challenges in IVF today is how to increase pregnancy rates and the likelihood of delivering healthy babies after embryo transfer. According to Dr. Pham Dinh Minh, the embryo is the decisive factor determining the success of an IVF cycle. Selecting the best embryo not only affects implantation rates but also has long-term implications for the child’s future health.

In this context, the application of artificial intelligence in preimplantation genetic testing (PGT-AI) is considered a highly promising trend. PGT-AI goes beyond the assessment of chromosomal abnormalities in embryos and aims to select the “best embryo among good embryos” from a genetic perspective.

Eurofins GENTIS Is researching the application of AI to predict embryo transfer success

Currently, Eurofins GENTIS is conducting pilot studies on applying AI to predict the success potential of embryo transfer. By analyzing the genetic data of embryos in combination with maternal clinical factors, AI can help identify relationships between embryos and their compatibility with the uterine environment. This enables clinicians to make optimal embryo selection decisions, thereby improving implantation rates and overall IVF success.

By integrating maternal clinical data and expanding the analysis of embryonic genetic data within PGT-AI, the research team at Eurofins GENTIS is developing screening and predictive models to identify healthy embryos with high implantation potential. This is regarded as an important step toward personalized counseling and assisted reproductive treatment.

Applications of AI in NIPT and newborn screening

In addition to IVF and PGT-AI, AI is also being strongly applied by Eurofins GENTIS in the fields of prenatal and newborn screening. In non-invasive prenatal testing (NIPT), Eurofins GENTIS collaborates with the University of Engineering and Technology – Vietnam National University, Hanoi, to develop bioinformatics algorithms that expand the detection spectrum of genetic variants. As a result, the sensitivity, accuracy, and specificity of NIPT have been significantly improved, contributing to higher-quality fetal anomaly screening.

Eurofins GENTIS Is researching and applying AI and Information technology in newborn screening

For newborn screening, Eurofins GENTIS is developing AI-integrated software solutions to enhance the detection of complex metabolic disorders based on mass spectrometry data. From these datasets, algorithms are built to support rapid and accurate early prediction and diagnosis of genetic diseases related to metabolic disorders in newborns.

Notably, in the process of reporting results, Eurofins GENTIS has integrated information technology and AI to interpret testing data, helping clinicians and families more easily access disease-related information, understand risks, and determine appropriate treatment directions for infants.

The application of AI and Omics data in genetic testing and counseling is ushering in a new era for assisted reproduction and precision medicine. With ongoing research and real-world applications, Eurofins GENTIS demonstrates its pioneering role in bringing advanced technologies into reproductive healthcare services in Vietnam.

In the future, as datasets become more comprehensive and AI algorithms more refined, AI-based genetic solutions are expected to support clinicians in making more accurate decisions, optimizing treatment outcomes, creating opportunities for parenthood for many infertile couples, and contributing to sustainable improvements in population health.

[content_more] => [meta_title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling [meta_description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1404 [category_id] => 15 ) [2] => stdClass Object ( [id] => 1398 [id_crawler] => [category_product] => NULL [thumbnail] => 605764480_1275897227908799_5804145375518154194_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-29 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-29 08:29:14 [updated_time] => 2026-01-15 09:52:40 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Congratulations-on-the-successful-December-prenatal-class-The-journey-to-happy-motherhood-of-Andrology-and-Fertility-hospital-of-Hanoi [title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi [description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels. [content] =>

Prenatal class – A strong foundation for the journey of motherhood

Pregnancy and childbirth are sacred journeys, yet they are also accompanied by many worries and concerns, especially for first-time mothers or families who have experienced the long and challenging journey of infertility. Understanding this, Hanoi Andrology and Fertility Hospital, in collaboration with the Happy Home Association, organized the Prenatal Class – The Journey to Happy Motherhood with the hope of providing expectant mothers with scientific knowledge, emotional stability, and the most comprehensive preparation before their delivery day.

From early morning, the hall welcomed a large number of expectant mothers and their families, creating a warm, intimate atmosphere filled with positive energy. The enthusiastic participation of families clearly reflected the strong demand for systematic prenatal education and the trust they place in the hospital’s medical team.

Experienced doctors accompanying Parents-to-be

The program was honored to have the direct participation and sharing of experienced obstetrics and gynecology specialists from Hanoi Andrology and Fertility Hospital:
Dr. Nguyen Thi Hong Nhung, Specialist in Obstetrics and Gynecology, and Dr. Dam Dinh Tam, Specialist in Obstetrics and Gynecology.

With solid professional expertise and years of experience accompanying thousands of childbirth cases, the doctors delivered practical, easy-to-understand, and highly relevant information. The class focused on key concerns such as physical changes during pregnancy, signs of labor, natural birth and cesarean section procedures, pain management during labor, postpartum care for both mother and baby, as well as psychological preparation for welcoming the newborn.

Beyond one-way knowledge sharing, the doctors devoted significant time to directly answering every question from expectant mothers and their families — from simple concerns about nutrition and safe exercise to deeper worries about the childbirth process — all were carefully listened to and thoroughly advised.

Providing official medical knowledge – Confidence for a safe delivery

One of the most outstanding values of the prenatal class was the provision of official medical knowledge based on professional guidelines and clinical practice. This helped expectant mothers avoid misleading and unverified information widely circulating on social media.

Through the class, mothers gained a better understanding of their own bodies, learned how to listen to changes during pregnancy, and recognized early signs that require medical attention. More importantly, with sufficient knowledge and strong psychological preparation, mothers felt much more confident and reassured when approaching childbirth — a sacred and unforgettable milestone in life.

Many participants shared that after the session, they felt more relaxed, less anxious, and more confident about the journey ahead. This is precisely the goal Hanoi Andrology and Fertility Hospital always strives for when organizing its regular prenatal classes.

A loving connection space for the whole family

Not only for expectant mothers, the prenatal class also created an opportunity for future fathers and family members to join, listen, and better understand the journey of pregnancy and childbirth. Family support is a powerful source of emotional strength, helping mothers feel more secure and happy.

The class atmosphere was open and friendly, where everyone could share their own stories, emotions, and experiences. This meaningful connection helped form a warm community where families prepared for parenthood with a proactive and positive mindset.

Eurofins GENTIS – Proud to be the accompanying sponsor

Contributing significantly to the success of the program, Eurofins GENTIS was honored to be the accompanying sponsor of the Prenatal Class – The Journey to Happy Motherhood. With the mission of providing high-quality testing solutions and healthcare services, Eurofins GENTIS continuously supports Vietnamese families in achieving safe and healthy pregnancies and childbirth.

Their companionship not only ensured a well-organized and meaningful program but also reflected a long-term commitment to maternal and child healthcare, especially during the prenatal stage — the foundation for a child’s comprehensive development in the future.

In the coming time, Eurofins GENTIS will continue accompanying the regular prenatal classes of Hanoi Andrology and Fertility Hospital, contributing to the best possible physical and emotional preparation for expectant mothers before childbirth. Because Eurofins GENTIS understands that each class is not just a knowledge-sharing session, but also a meaningful milestone that builds mothers’ confidence, strengthens family bonds, and makes the journey of parenthood gentler and happier.

The Prenatal Class – The Journey to Happy Motherhood on December 27, 2025 concluded in a warm atmosphere filled with joy and trust. The success of the program once again affirms the continuous efforts of Hanoi Andrology and Fertility Hospital in providing comprehensive care for families, along with the valuable support of partners such as Eurofins GENTIS.

We wish all expectant mothers good health, peace of mind, a fulfilling pregnancy, and a smooth, gentle delivery. May all families soon welcome their beloved babies, opening a new chapter filled with happiness and love.

[content_more] => [meta_title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andro [meta_description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1398 [category_id] => 15 ) [3] => stdClass Object ( [id] => 1397 [id_crawler] => [category_product] => NULL [thumbnail] => 299d08137c20f37eaa31.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-26 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-26 15:55:42 [updated_time] => 2026-01-14 15:50:20 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-&-andrology-and-fertility-hospital-of-Hanoi-announce-research-on-recurrent-pregnancy-loss-The-role-of-multigene-sequencing-in-genetic-screening-and-counseling [title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling [description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research. [content] =>

The study was conducted with the objective of investigating the spectrum of genetic variants detected by FertiScan™ (a test designed to identify genetic abnormalities associated with female infertility and recurrent pregnancy loss) in women with a history of recurrent miscarriage.

The study population consisted of 20 infertile women with a history of recurrent pregnancy loss (RPL). RPL was defined as two or more consecutive spontaneous miscarriages before 20 weeks of gestation at the Hanoi Hospital of Andrology and Infertility from May to August 2023.

The study indicates that recurrent miscarriage and repeated fetal loss are common challenges in assisted reproductive practice, affecting approximately 1–5% of women of reproductive age. In addition to uterine anatomical, endocrine, immunohematological, and infectious causes, genetic factors play an important role but are not easily detected by routine testing. The cause of miscarriage remains unknown in more than 50% of these cases.

Karyotype analysis and microarray testing are useful for identifying chromosomal numerical and structural abnormalities, but they remain limited in detecting single-gene causes related to oocyte development, meiosis, implantation, and early embryonic viability. Therefore, targeted molecular genetic approaches are receiving increasing attention.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss. Among these, the FertiScan™ Global Female Infertility Panel is a representative tool, covering more than 70 genes involved in key pathogenic mechanisms including premature ovarian failure and ovarian dysfunction, ovarian dysgenesis, defects in oocyte maturation, abnormal oocyte–zona pellucida–fertilization interactions, genes affecting implantation and endometrial signaling, as well as DNA repair genes associated with early embryonic lethality.

This approach not only increases the detection rate of clinically significant genetic variants but also supports personalized counseling and intervention strategies, including partner testing in autosomal recessive disorders, indications for PGT-M or PGT-SR, and prenatal genetic screening when appropriate.

In Vietnam, data on the prevalence of genetic variants in women with unexplained recurrent pregnancy loss remain limited. This gap restricts optimal prognostic counseling and personalized treatment, particularly in cases with normal karyotype results but persistent pregnancy loss.

The implementation of specialized targeted NGS panels such as FertiScan™ provides value in identifying subsets of patients carrying pathogenic or likely pathogenic variants truly associated with reproductive biological mechanisms, and in documenting variants of uncertain significance (VUS) within the Vietnamese population in order to gradually standardize variant interpretation according to the classification guidelines of the American College of Medical Genetics and Genomics (ACMG). FertiScan™ results are interpreted following ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification guidelines, including pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), and benign/likely benign. Variant classification is always considered within the specific clinical and family context to ensure individual appropriateness.

From an application perspective, FertiScan™ enhances the detection of monogenic causes in patients with recurrent pregnancy loss, particularly in cases without chromosomal abnormalities identified by karyotype or microarray. The test also supports personalized genetic counseling, including partner testing in recessive genetic conditions, recommendations for PGT-M/PGT-SR, and the development of appropriate prenatal or preconception screening plans. Furthermore, FertiScan™ demonstrates strong potential for application in genetic epidemiology research in Vietnam, contributing to the establishment of population-based variant databases, thereby improving the accuracy of variant interpretation and the quality of diagnosis, counseling, and future interventions.

These results highlight the importance of systematically integrating genetic testing into the evaluation of recurrent miscarriage and fetal loss, with multigene testing positioned within structured pre- and post-test counseling and long-term follow-up strategies.

With the mission of “Enhancing the intellectual and physical well-being of the Vietnamese people,” Eurofins GENTIS continues its collaboration with the Hanoi Hospital of Andrology and Infertility to implement high-value medical research and to further develop a comprehensive ecosystem of advanced genetic testing. Through these efforts, Eurofins GENTIS contributes to delivering modern healthcare solutions and supporting medical professionals in improving reproductive healthcare for the community.

[content_more] => [meta_title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy [meta_description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue N [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1397 [category_id] => 15 ) [4] => stdClass Object ( [id] => 1396 [id_crawler] => [category_product] => NULL [thumbnail] => 06f14a7e3e4db113e85c.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-26 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-26 08:41:18 [updated_time] => 2026-01-14 15:41:21 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-&-Andrology-and-fertility-hospital-of-Hanoi-publish-research-findings-on-recurrent-pregnancy-loss-in-the-journal-of-medical-research [title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research [description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL). [content] =>

The research findings were presented in the scientific article entitled: “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” which was published in Journal of Medical Research, Issue No. 197, December 2025 — a prestigious journal featuring original research and review articles in basic medicine, clinical medicine, preventive medicine, public health, and medical sociology, aimed at advancing medical knowledge and practice.

The study was conducted on 20 infertile patients with a history of recurrent pregnancy loss at the Hanoi Hospital of Andrology and Infertility between May and August 2023. According to experts, recurrent miscarriage and fetal loss represent a major challenge in assisted reproduction, affecting approximately 1–5% of women of reproductive age.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, significantly expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss.

Among these tools, the FertiScan™ Global Female Infertility Panel is particularly comprehensive, covering more than 70 genes involved in key pathogenic mechanisms, including: Premature ovarian failure and ovarian dysfunction. Ovarian dysgenesis. Oocyte maturation defects. Abnormal oocyte–zona pellucida–fertilization interactions. Genes affecting implantation and endometrial signaling. DNA repair genes associated with early embryonic lethality

In this study, researchers used the FertiScan™ Global Female Infertility Panel (70 genes) based on NGS technology to simultaneously examine coding regions and splice sites of the target genes.

Among the 20 patients, 12 cases (60%) carried ≥ 1 reproduction-related genetic variant, including: 4 patients harboring pathogenic or likely pathogenic variants (P/LP). Predominantly in the heterozygous state of autosomal recessive disorders.

A substantial proportion of detected variants were classified as variants of uncertain significance (VUS). Notably, variants were identified in genes with well-established biological roles, such as CEP250, TACR3, NOBOX, ZP1, and others.

The FertiScan™ test which identifies genetic causes of infertility and rare hereditary abnormalities associated with female infertility and recurrent miscarriage, as well as evaluates male reproductive health — significantly enhances the detection of monogenic causes in patients with RPL, particularly in cases without chromosomal abnormalities detected by karyotyping or microarray analysis.

The test also supports personalized genetic counseling, including: Partner testing in autosomal recessive conditions. Indications for PGT-M (preimplantation genetic testing for monogenic diseases). PGT-SR (preimplantation genetic testing for structural chromosomal rearrangements). Development of tailored prenatal and preconception screening strategies

Beyond its clinical value, FertiScan™ demonstrates strong potential in genetic epidemiology research in Vietnam, contributing to the establishment of population-specific variant databases and thereby improving variant interpretation, diagnostic accuracy, counseling, and future clinical interventions.

Researchers concluded that multigene testing such as FertiScan™ significantly improves the detection of underlying causes in unexplained RPL cases, particularly when integrated into comprehensive pre- and post-test counseling and long-term follow-up.

Sharing insights on the study, Dr. Pham Dinh Minh, R&D Director of Eurofins GENTIS and co-author of the publication, stated:“Publishing in the Journal of Medical Research is a long journey — from idea generation, study implementation, data analysis, manuscript preparation, submission, to rigorous peer review. Beyond scientific merit, the research must demonstrate strict methodological rigor and data integrity. We spent more than three months collecting data and over two years completing the project. The publication of this work is a source of pride for our team and opens new avenues for research in infertile women with recurrent pregnancy loss, helping realize the dream of parenthood for many couples and highlighting the immense potential of genetic applications in reproductive medicine in Vietnam.”

Through systematically conducted research and publication in prestigious scientific journals, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility continue to reaffirm their joint commitment to advancing genetic research and its integration into clinical practice — contributing to improved diagnostic and treatment quality in assisted reproduction across Vietnam.

[content_more] => [meta_title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent p [meta_description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1396 [category_id] => 15 ) [5] => stdClass Object ( [id] => 1395 [id_crawler] => [category_product] => NULL [thumbnail] => 603924137_1486168513515857_3858940485546585452_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-25 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-25 13:18:45 [updated_time] => 2026-01-14 15:26:26 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-pioneers-the-deployment-of-Next-generation-sequencing-technology-MiSeq-i100-Plus-in-Vietnam [title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in Vietnam [description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirms Eurofins GENTIS’s long-term commitment to continuously advancing genetic diagnostic capabilities and aligning with the highest standards of modern global medicine. [content] =>

The MiSeq i100 Plus is Illumina’s newest benchtop sequencer — from the world’s leading brand in NGS technology. More than a conventional sequencing instrument, the MiSeq i100 Plus represents a significant leap forward in performance, speed, and accuracy, meeting the ever-growing demands of clinical and research laboratories.

Eurofins GENTIS’s pioneering adoption of this system clearly reflects its strategic, long-term investment vision to deliver the most advanced genetic testing solutions to the community.

One of the most outstanding advantages of the MiSeq i100 Plus is its exceptional sequencing speed. By leveraging advanced chemistry and an optimized workflow, the system significantly shortens run times, enabling many NGS-based tests to deliver same-day results while maintaining high accuracy and data reliability.

This capability is particularly critical in clinical settings requiring rapid decision-making, allowing physicians to implement timely and effective treatment strategies.

In addition to speed, the MiSeq i100 Plus features a “Touch & Run” plug-and-play design, simplifying complex technical procedures. The integrated reagent cartridge minimizes manual preparation steps, thereby reducing human error and enhancing consistency between runs. With its user-friendly design and high level of automation, Eurofins GENTIS’s technical team can operate the system smoothly and reliably, while dedicating greater focus to in-depth analysis and rigorous quality control.

The system incorporates Illumina’s proprietary XLEAP-SBS™ technology, delivering superior read quality and significantly improving the accuracy and reliability of sequencing data. This allows the platform to precisely detect and analyze complex genetic variants, meeting the stringent requirements of modern genetic testing across both clinical and research applications.

With installation, technology transfer, and continuous technical support from Mitalab, Eurofins GENTIS is maximizing the capabilities of the MiSeq i100 Plus across multiple critical fields of medicine and molecular biology.

NGS enables accurate analysis of chromosomal abnormalities and pathogenic genetic variants, significantly enhancing reproductive health counseling and care, and helping many families realize their dream of parenthood.

The MiSeq i100 Plus plays a pivotal role in early detection of cancer-related genetic mutations, comprehensive tumor genomic profiling, and the development of targeted treatment regimens.
This forms the foundation of precision medicine, where each patient receives therapies tailored to their unique genetic profile — improving treatment outcomes and quality of life.

The system expands capabilities in diagnosing rare diseases and conducting high-sensitivity microbial studies, enabling the detection of novel or hard-to-identify pathogens beyond the limits of conventional methods.
These advancements contribute not only to clinical effectiveness but also to biomedical research and healthcare development in Vietnam.

Becoming the first organization in Vietnam to deploy the MiSeq i100 Plus once again reinforces Eurofins GENTIS’s leadership position in genetic testing and diagnostics.
This milestone reflects not only technological achievement but also the company’s strategic vision, deep professional expertise, and long-term commitment to bringing the world’s most advanced medical technologies closer to the Vietnamese community.

Looking ahead, Eurofins GENTIS will continue making strong investments in technological infrastructure, human resources, and international collaboration — partnering with the healthcare sector to elevate diagnostic quality, advance personalized medicine, and safeguard public health.

[content_more] => [meta_title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in [meta_description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirm [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1395 [category_id] => 15 ) [6] => stdClass Object ( [id] => 1393 [id_crawler] => [category_product] => NULL [thumbnail] => dsc09793.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-12-18 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-18 09:02:36 [updated_time] => 2025-12-18 11:21:18 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Preimplantation-genetic-testing-A-key-to-improving-IVF-success-and-protecting-future-generations [title] => Preimplantation genetic testing: A key to improving IVF success and protecting future generations [description] => In recent years, in vitro fertilization (IVF) has become a vital solution helping tens of thousands of Vietnamese couples realize their dream of parenthood. [content] =>

Each year, approximately 50,000 IVF cycles are performed in Vietnam, making the country one of the fastest-growing IVF markets in the region. However, alongside this growth come increasingly evident challenges: how to improve success rates, reduce the number of embryo transfers, optimize treatment costs, and—most importantly—ensure the long-term birth of healthy babies. Advanced genetic solutions are playing a pivotal role, laying the foundation for modern, precise, and sustainable reproductive medicine. IVF success rates vary by center and patient age; they are commonly reported at around 40–50% in younger patient groups and decline significantly with increasing maternal age, as well as other influencing factors such as oocyte and sperm quality, endometrial conditions, and embryo quality.

Preimplantation Genetic Testing (PGT) has become one of the most important tools for enhancing the quality of IVF treatment. PGT enables genetic evaluation of embryos prior to uterine transfer, thereby supporting the selection of embryos with high implantation potential and reducing the risk of genetic abnormalities. At EUROFINS GENTIS, a comprehensive PGT testing system—including PGT-A, PGT-SR, PGT-M, PGT-NEXT, and PGT-UPGRADE—is implemented in an integrated manner, providing physicians and patients with stronger scientific evidence to select optimal embryos, minimize risks, and improve IVF success rates.

PGT-M – Protecting future generations from monogenic genetic disorders

In addition to chromosomal abnormalities, monogenic genetic disorders continue to silently affect the health and happiness of many Vietnamese families. These conditions are often detected only after birth, leading to long-term treatment burdens and significantly impacting the quality of life of families and society as a whole.

Prof. Dr. Nguyen Dinh Tao (Chairman of Hanoi Assisted Reproduction) has highlighted PGT-M at EUROFINS GENTIS as a pioneering solution in early genetic disease prevention strategies. He noted that PGT-M enables accurate detection of known disease-causing mutations identified in parents or within families, allowing for the screening and selection of unaffected embryos prior to transfer. A key strength of PGT-M at EUROFINS GENTIS lies in its closed-loop and highly individualized process, which includes in-depth genetic counseling, identification of disease-related mutations, tailored test strategy design, and embryo genetic analysis using next-generation sequencing (NGS) technology. This solution can be applied to a wide range of genetic disorders, including rare diseases, opening opportunities for healthy childbirth among high-risk couples. Beyond its clinical value in establishing pregnancies unaffected by specific inherited traits—such as known pathogenic variants carried by one or both parents—PGT-M also helps reduce long-term treatment burdens, lower societal healthcare costs, and improve overall population health.

PGT-AI – AI breakthroughs in reproductive genetics

Alongside rapid advances in digital technology, artificial intelligence (AI) and bioinformatics are driving profound changes in reproductive medicine. Beyond genetic data analysis alone, AI enables the integration of multiple data sources—such as embryo imaging, molecular biology data, and clinical factors—thereby generating more accurate predictive models of embryo implantation potential and developmental outcomes.

Speaking at the HASAM 2025 conference, Dr. Pham Dinh Minh (R&D Director, EUROFINS GENTIS) introduced a new test researched and piloted by EUROFINS GENTIS: PGT-AI (icOne)—an advanced AI algorithm certified by the FDA, enabling in-depth analysis of embryo genetic data using modern machine learning platforms. This technology overcomes limitations of traditional PGT methods and supports more precise and personalized clinical decision-making for each patient.

Dr. Minh further noted that EUROFINS GENTIS is currently the exclusive partner implementing PGT-AI (icOne) in Vietnam, marking a significant milestone in bringing world-leading medical technologies closer to domestic patients. The combination of AI, bioinformatics, and the extensive expertise of specialist teams has enhanced IVF effectiveness while optimizing treatment costs and patient experience.

International quality management systems – The foundation for PGT accuracy

In reproductive genetics, particularly PGT testing, quality management systems play a decisive role in ensuring accuracy and reliability of results, directly influencing embryo selection, IVF treatment outcomes, and the future of each family. According to Dr. Nguyen Quang Vinh (Laboratory Director, EUROFINS GENTIS): “The comprehensive quality management system at EUROFINS GENTIS is built and operated in accordance with strict international standards such as ISO 15189, CAP, and CLSI. This ensures standardization across the entire PGT testing workflow—from receiving embryo biopsy samples, DNA processing, NGS and bioinformatics data analysis, to final reporting. Rigorous control at every step not only minimizes technical errors and ensures consistency and reproducibility of results, but also enhances safety, data security, and traceability, thereby supporting more accurate clinical decision-making.”

Together with internationally accredited laboratories, strict DNA contamination control environments, and highly experienced experts, EUROFINS GENTIS maintains high reliability in PGT testing while establishing a solid foundation for implementing advanced technologies such as PGT-AI—contributing to improved IVF outcomes and strengthening the trust of IVF centers and patients nationwide.

Accompanying the journey to parenthood

Guided by science, technology, and quality, EUROFINS GENTIS not only provides advanced genetic testing services but also serves as a trusted partner to IVF centers and Vietnamese families on their journey toward parenthood. Through the application of modern genetic technologies, EUROFINS GENTIS is steadily contributing to higher IVF success rates, early prevention of genetic diseases, and the sustainable development of reproductive medicine in Vietnam.

[content_more] => [meta_title] => Preimplantation genetic testing: A key to improving IVF success and protecting future generations [meta_description] => Preimplantation Genetic Testing (PGT) has become one of the most important tools for enhancing the quality of IVF treatment. PGT enables genetic evaluation of embryos prior to uterine transfer, thereby supporting the selection of embryos with high implant [meta_keyword] => GENTIS,PGT [thumbnail_alt] => [post_id] => 1393 [category_id] => 15 ) [7] => stdClass Object ( [id] => 1392 [id_crawler] => [category_product] => NULL [thumbnail] => 596067328_1263300952501760_1825096505615856739_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-11-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-12 15:41:15 [updated_time] => 2025-12-22 11:35:26 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-partners-with-Hanoi-hospital-of-andrology-and-infertility-to-host-the-december-prenatal-class [title] => Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prenatal class [description] => The journey of pregnancy is a sacred experience, one filled with unique emotions for every mother. It is the overwhelming joy of discovering the presence of a beloved baby, the day-by-day anticipation of feeling those first tiny movements, and at the same time, countless questions and concerns about health, nutrition, labor, and newborn care. [content] =>

Understanding these concerns, Eurofins GENTIS is proud to partner with the Hanoi Hospital of Andrology and Infertility (AF HANOI) to organize the Prenatal Class – The Journey to Happy Motherhood, offering expectant mothers a warm, supportive space to gain knowledge and meaningful connection.

A special space for expectant mothers – where the journey to motherhood becomes sweeter

The prenatal class is not simply a session on pregnancy knowledge; it is a place where mothers-to-be and fathers-to-be can find reassurance, support, and love. It is an opportunity for future parents to prepare a solid foundation together before welcoming their little angel.

AF HANOI and Eurofins GENTIS aim to create a gentle, friendly learning environment where every mother feels comfortable sharing her concerns and receiving guidance from leading experts in obstetrics and gynecology.

Expert participation – the highlight of the Prenatal Class

At this session, expectant mothers will have the opportunity to listen to practical and valuable professional insights from two experienced doctors:

Dr. Nguyen Thi Hong Nhung, MD – Specialist in Obstetrics & Gynecology
Dr. Dam Dinh Tam, MD – Specialist in Obstetrics & Gynecology

With many years of experience accompanying pregnant women, these experts will deliver a friendly, practical, and informative session, helping young parents better understand fetal development and the changes in the mother’s body throughout pregnancy.

Prenatal Class – The journey to happy motherhood includes a wide range of topics, such as:

Essential knowledge on prenatal care
Mothers will be guided on appropriate nutrition, gentle exercises, proper health monitoring, warning signs to watch for, and ways to care for mental well-being to stay positive throughout the nine months and ten days of pregnancy.

Understanding labor and achieving a safe delivery
From signs of labor and bodily changes, to proper breathing and pushing techniques, and preparing a hospital bag—everything will be explained in detail by doctors to help mothers feel more confident during this important moment.

Scientific newborn care from the very first days of life
Caring for a newborn is always a major challenge, especially for first-time mothers. In the class, mothers will learn essential basics such as proper breastfeeding, bathing a baby, and handling common newborn issues.

Comprehensive Q&A from A to Z
Beyond passive learning, expectant mothers can ask doctors questions directly. Any concern—no matter how small—will be answered thoughtfully and thoroughly by the experts.

AF HANOI and Eurofins GENTIS hope to spread a sense of calm and reassurance to all participating mothers. Therefore, each mother will receive a small gift as a wish for a healthy pregnancy and a gentle, fulfilling motherhood journey.

Event Information

Time: 09:30 – 11:00, Saturday, December 27, 2025
Venue: 5th Floor Auditorium – Hanoi Hospital of Andrology and Infertility
Register now: forms.gle/kn6tj49GxxyqjbZy5
Or scan the QR code in the image to secure your seat early!

Seats are limited to ensure the quality of the class, so expectant mothers are encouraged to register early to avoid missing out.

Eurofins GENTIS – Accompanying mothers through every loving moment

Eurofins GENTIS deeply values every mother’s journey and believes that when mothers are well prepared with knowledge and emotional readiness, pregnancy becomes the most beautiful and peaceful time of life. By partnering with AF HANOI in this prenatal class, GENTIS hopes to bring mothers:

Peace of mind in every decision
Proactive confidence throughout pregnancy
Love that reaches babies from the very first days of life

Throughout a mother’s journey—from preconception, through pregnancy, to early childcare—Eurofins GENTIS is always ready to support with advanced genetic testing solutions, ensuring comprehensive and science-based care for both mother and baby.

In just one morning, mothers gain knowledge, connection, confidence, and love. That is the goal of the prenatal class and the values Eurofins GENTIS wishes to share.

Wishing all mothers a safe, healthy, and happiness-filled pregnancy.

[content_more] => [meta_title] => Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prena [meta_description] => The journey of pregnancy is a sacred experience, one filled with unique emotions for every mother. It is the overwhelming joy of discovering the presence of a beloved baby, the day-by-day anticipation of feeling those first tiny movements, and at the same [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1392 [category_id] => 15 ) )

Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing

In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle.

Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling

In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling.

Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi

On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels.

Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling

Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research.

Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research

Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL).

Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in Vietnam

Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirms Eurofins GENTIS’s long-term commitment to continuously advancing genetic diagnostic capabilities and aligning with the highest standards of modern global medicine.

Preimplantation genetic testing: A key to improving IVF success and protecting future generations

In recent years, in vitro fertilization (IVF) has become a vital solution helping tens of thousands of Vietnamese couples realize their dream of parenthood.

Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prenatal class

The journey of pregnancy is a sacred experience, one filled with unique emotions for every mother. It is the overwhelming joy of discovering the presence of a beloved baby, the day-by-day anticipation of feeling those first tiny movements, and at the same time, countless questions and concerns about health, nutrition, labor, and newborn care.